Protein Regulates Sunburn Pain | July 11, 2011 Issue - Vol. 89 Issue 28 | Chemical & Engineering News
Volume 89 Issue 28 | p. 7 | News of The Week
Issue Date: July 11, 2011

Protein Regulates Sunburn Pain

drug target: Chemokine CXCL5 boosts skin’s tenderness
Department: Science & Technology
Keywords: sunburn, pain, chemokine, analgesics
Beachgoers who become sensitized to pain because of too much sun can blame a protein called CXCL5.
Credit: iStock
The sting of sunburn is mediated by a cytokine called CXCL5, researchers find.
Beachgoers who become sensitized to pain because of too much sun can blame a protein called CXCL5.
Credit: iStock

t he cell-signaling protein called CXCL5 plays a major role in the agony sunburn victims experience even from just a light slap on the back, according to a report in Science Translational Medicine (DOI: 10.1126/scitranslmed.3002193). A team led by Stephen B. McMahon of King’s College London found that sun-scorched human and rat skin produces CXCL5 at elevated levels and that the molecule increases sensitivity to pain in the tissue.

CXCL5 belongs to a family of proteins, known as chemokines, that can call inflammatory immune cells to an injured site. “This finding might be indicative of a more general role for CXCL5 in a variety of clinically relevant inflammatory pain conditions, for instance, osteoarthritis,” McMahon says. He and his team hope that their results will yield new, targeted pain medications.

In their study, the researchers biopsied the skin of humans and rats that had been exposed to ultraviolet B (UVB) radiation. They then studied the gene expression levels of more than 90 signaling proteins in the tissue. CXCL5 stood out from the pack, suggesting that it is responsible for a majority of sunburn-induced pain in both species.

McMahon’s team also administered an antibody against CXCL5 to rats that had been irradiated with UVB light. Compared with a control group, those rats had a much higher tolerance for pain in their sunburnt tissue.

But what is “unique” about this work, says Ru-Rong Ji, a pain researcher at Harvard Medical School, is that McMahon’s team initially isolated the chemokine from both human and rat tissues.

Traditionally, drug development programs start by identifying targets in animals and eventually moving to humans in the clinic, McMahon says. But humans and animals don’t always react to stimuli in the same way. “Our study has tried to validate an alternative approach,” he adds. “We have reversed the normal process” by starting with human biopsy to identify potential target molecules and then measuring their action in animals. “We think this might be a way of improving the drug discovery process,” McMahon says.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment